

Phone Number: (949) 491-8080

CLIA: 05D2040304

Patient: REPORT SAMPLE Specimen: Swab Patient ID: MDT-007 Patient DOB: 11/17/1998

Collected: 12/28/23 10:00 AM PST Received: 12/28/23 8:49 AM PST Reported: 12/28/23 8:51 AM PST

Specimen ID: 2238223 Provider: Provider Test

Account: 6518

Facility: Innovative Health Diagnos

# Molecular Report

Patient Age: 25

Patient Sex: Female

Powered by Eden Software Solutions



**Pathogens** 

Adenovirus, Haemophilus influenzae

#### **LEGEND**

SANFORD GUIDE

Every effort is made to ensure the accuracy of Sanford Guide content. However, current full prescribing information available in the package insert for each drug should be consulted before prescribing any product. The editors and publisher are not responsible for errors or omissions or for any consequences, such as injury, damage, or death, from application of our print and digital content, and make no warranty, express or implied, with respect to the currency, accuracy, or completeness of the contents of this publication. Application of this information in a particular situation remains solely the professional responsibility of the clinician.

The data provided are intended to serve as a general guide to antibacterial usefulness based on package insert, treatment guidelines, published reports, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in resistance patterns due to local or regional differences or as a consequence of clinical setting, e.g., community onset vs. ICU-acquired infection, should be taken into account when using this information because the activity of antimicrobial agents can differ significantly and hence is beyond the scope of this general summary. Susceptibility testing results and your local antibiogram should be consulted in every case.

- [1] Preferred: Agent is a first line therapy: reliably active in vitro, clinically effective, guideline recommended, recommended as a first-line agent or acceptable alternative agent in the Sanford Guide.
- [2] Alternative: Agent is a potential alternative agent (active in vitro, possesses class activity comparable to known effective agents or a therapeutically interchangeable agents and hence likely to be clinically effective, but second line due to overly broad spectrum, toxicity, limited clinical experience, or paucity of direct evidence of effectiveness).
- [3] Limited Utility: Limited utility such that the agent, although clinically effective in some settings or types of infections is not reliably effective in others, or should be used in combination with another agent, and/or its efficacy is limited by resistance which has been associated with treatment failure.

	Amox-Clav	Levofloxacin	Moxifloxacin	Cidofovir	Ciprofloxacin	Delafloxacin	Ofloxacin	Prulifloxacin	Gemifloxacin	Gatifloxacin	Cefprozil	Cefurox-Axe	Cefixime	Ceftibuten	Cefpodoxime	Cefdinir	Cefditoren	Azithrom ycin	Clarithromycin	Telithromycin	Doxycycline	Minocycline	Omadacycline	Tetracycline	Lefamulin
Pathogens																									
Adenovirus				2																					
H. influenzae	1	1	1		2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

Sanford Guide Content accessed on 12/28/23 8:51 AM PST. For information about treatment and prescribing options, please log in at https://lab.edenss.com/.



Phone Number: (949) 491-8080

CLIA: 05D2040304

Patient: REPORT SAMPLE
Patient ID: MDT-007

Specimen: Swab
Collected: 12/28/23 10:00 AM PST

Specimen ID: 2238223
Provider: Provider Test

Patient DOB: 11/17/1998
Patient Age: 25
Patient Sex: Female

Received: 12/28/23 8:49 AM PST Reported: 12/28/23 8:51 AM PST

Account: **6518**Facility: **Innovative Health Diagnos** 

#### Powered by **Eden Software Solutions**

Respiratory Pathogen Panel (RPP), Comprehensive		
Test	Result	Range
Bacteria		
Bordetella pertussis	Not Detected	Not Detected
Bordetella spp	Not Detected	Not Detected
Chlamydophila pneumoniae	Not Detected	Not Detected
Haemophilus influenzae	<b>✓</b> Detected	Not Detected
Klebsiella pneumoniae	Not Detected	Not Detected
Legionella pneumophila	Not Detected	Not Detected
Mycoplasma pneumoniae	Not Detected	Not Detected
Staphylococcus aureus	Not Detected	Not Detected
Streptococcus pneumoniae	Not Detected	Not Detected
Virus		
Adenovirus	<b>✓</b> Detected	Not Detected
HHV4 (Epstein-Barr Virus)	Not Detected	Not Detected
HHV5 (Cytomegalovirus)	Not Detected	Not Detected
HHV6 (Human Herpesvirus 6)	Not Detected	Not Detected
Human Coronavirus 229E	Not Detected	Not Detected
Human Coronavirus HKU1	Not Detected	Not Detected
Human Coronavirus NL63	Not Detected	Not Detected
Human Coronavirus OC43	Not Detected	Not Detected
Human Enterovirus (pan assay)	Not Detected	Not Detected
Human Enterovirus D68	Not Detected	Not Detected
Human Metapneumovirus (hMPV)	Not Detected	Not Detected
Human Parainfluenza Virus 1	Not Detected	Not Detected
Human Parainfluenza Virus 2	Not Detected	Not Detected
Human Parainfluenza Virus 3	Not Detected	Not Detected
Human Parainfluenza Virus 4	Not Detected	Not Detected
Influenza A (Pan)	Not Detected	Not Detected
Influenza A/H1-2009	Not Detected	Not Detected
Influenza A/H3	Not Detected	Not Detected
Influenza B	Not Detected	Not Detected
Respiratory Syncytial Virus A (RSV A)	Not Detected	Not Detected
Respiratory Syncytial Virus B (RSV B)	Not Detected	Not Detected
Rhinovirus	Not Detected	Not Detected



Phone Number: (949) 491-8080

CLIA: 05D2040304

Patient: REPORT SAMPLE Patient ID: MDT-007

Patient Age: 25

Patient Sex: Female

Patient DOB: 11/17/1998

Collected: 12/28/23 10:00 AM PST Received: 12/28/23 8:49 AM PST Reported: 12/28/23 8:51 AM PST

Specimen: Swab

Specimen ID: 2238223 Provider: **Provider Test** 

Account: 6518

Facility: Innovative Health Diagnos

Virus

SARS-CoV-2 **Not Detected** Not Detected

These tests are Lab Developed Tests and were developed, and its performance characteristics determined by Innovative Health Diagnostics. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used solely for clinical diagnosis or patient management decisions.

#### Comments:

No comments.



Phone Number: (949) 491-8080

CLIA: 05D2040304

Patient: REPORT SAMPLE Specimen: Swab Specimen ID: 2238223 Patient ID: MDT-007 Collected: 12/28/23 10:00 AM PST Provider: Provider Test Patient DOB: 11/17/1998 Received: 12/28/23 8:49 AM PST Account: 6518

Patient Age: 25 Reported: 12/28/23 8:51 AM PST Facility: Innovative Health Diagnos Patient Sex: Female

### **Molecular Report**

Powered by Eden Software Solutions

### Detected Pathogen - Adenovirus



Every effort is made to ensure the accuracy of Sanford Guide content. However, current full prescribing information available in the package insert for each drug should be consulted before prescribing any product. The editors and publisher are not responsible for errors or omissions or for any consequences, such as injury, damage, or death, from application of our print and digital content, and make no warranty, express or implied, with respect to the currency, accuracy, or completeness of the contents of this publication. Application of this information in a particular situation remains solely the professional responsibility of the clinician.

The data provided are intended to serve as a general guide to antibacterial usefulness based on package insert, treatment guidelines, published reports, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in resistance patterns due to local or regional differences or as a consequence of clinical setting, e.g., community onset vs. ICU-acquired infection, should be taken into account when using this information because the activity of antimicrobial agents can differ significantly and hence is beyond the scope of this general summary. Susceptibility testing results and your local antibiogram should be consulted in every case.

## Clinical Setting

- Cause of respiratory tract infections, including fatal pneumonia, in children and young adults.
  - Adenovirus 14 associated with severe pneumonia in otherwise healthy young adults (MMWR 56(45):1181, 2007).
  - High mortality (60%) in transplant patients (Clin Infect Dis 43:331, 2006).
    - Frequent cause of hemorrhagic cystitis
    - Clinical syndromes include: fever, elevated liver enzymes, leukopenia, thrombocytopenia, diarrhea, pneumonia, hemorrhagic cystitis, and rarely, meningoencephalitis.
- Monitor for viremia (1 2 times / week) in those with Allo-HSCT with haploidentical donor or unrelated cord blood graft; Severe GVHD; Severe lymphopenia; and / or therapy with alemtuzaumab (Campath). Monitoring should continue until immune reconstitution. Those with at least 1 risk factor and viremia should be treated with Cidofovir.
- Outbreaks in institutional settings have been reported (Am J Infect Control 35:S65, 2007). CDC/HICPAC guidelines recommend contact and droplet precautions during hospitalization for the duration of illness to prevent nosocomial transmission; extended duration of precautions may be required for immunocompromised patients owing to prolonged shedding.

#### Prevention

Sanford Guide Content accessed on 12/28/23 8:51 AM PST and truncated by Innovative Health Diagnostics.

#### **VIEW FULL PATHOGEN ARTICLE HERE**

For information about treatment and prescribing options, please log in at https://lab.edenss.com/ | Powered by Eden Software Solutions

## Detected Pathogen - Haemophilus influenzae



Every effort is made to ensure the accuracy of Sanford Guide content. However, current full prescribing information available in the package insert for each drug should be consulted before prescribing any product. The editors and publisher are not responsible for errors or omissions or for any consequences, such as injury, damage, or death, from application of our print and digital content, and make no warranty, express or implied, with respect to the currency, accuracy, or completeness of the contents of this publication. Application of this information in a particular situation remains solely the professional responsibility of the clinician.

The data provided are intended to serve as a general guide to antibacterial usefulness based on package insert, treatment guidelines, published reports, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in resistance patterns due to local or regional differences or as a consequence of clinical setting, e.g., community onset vs. ICU-acquired infection, should be taken into account when using this information because the activity of antimicrobial agents can differ significantly and hence is beyond the scope of this general summary. Susceptibility testing results and your local antibiogram should be consulted in every case.



Phone Number: (949) 491-8080

CLIA: 05D2040304

Patient DOB: Patient Account: Patient Account: Patient Service REPORT SAMPLE Specimen: Swab Specimen ID: 2238223

Specimen ID: 2238223

Collected: 12/28/23 10:00 AM PST Provider: Provider Test Account: 6518

Patient Age: 25
Reported: 12/28/23 8:51 AM PST
Patient Sex: Female

Received: 12/28/23 8:51 AM PST
Facility: Innovative Health Diagnos

# Clinical Setting

- Isolation of Haemophilus influenzae in culture of CSF, blood, sputum, respiratory tract secretions or tissue.
  - Encapsulated type B strains (HiB), as well as other typable strains A, C, E, F, typically cause more invasive disease, but HiB preventable by vaccination.
  - Nontypeable strains cause most disease in adults and vaccinated children.
- Frequent colonizer.
- Choice of regimen depends on disease or severity of illness.
- For specific therapy in the following settings, see:
  - o Meningitis, H. influenzae
  - Empyema, Infants/Young Children
  - Empyema, Older Child/Adult
  - o Sepsis, Child
  - Epiglottitis, Supraglottis
  - Bronchiectasis
  - Bronchitis, Infants/Children (Age < 5 years)
  - o Bacteremia, Post-splenectomy
  - Acute otitis media

Sanford Guide Content accessed on 12/28/23 8:51 AM PST and truncated by Innovative Health Diagnostics.

#### **VIEW FULL PATHOGEN ARTICLE HERE**

For information about treatment and prescribing options, please log in at https://lab.edenss.com/ | Powered by Eden Software Solutions